Home » Stocks » VBIV

VBI Vaccines, Inc. (VBIV)

Stock Price: $3.07 USD 0.17 (5.86%)
Updated Jul 28, 2021 4:00 PM EDT - Market closed
After-hours: $3.08 +0.01 (0.33%) Jul 28, 7:47 PM
Market Cap 780.38M
Revenue (ttm) 947,000
Net Income (ttm) -55.52M
Shares Out 254.20M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 28
Last Price $3.07
Previous Close $2.90
Change ($) 0.17
Change (%) 5.86%
Day's Open 2.86
Day's Range 2.86 - 3.09
Day's Volume 2,025,577
52-Week Range 2.07 - 5.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 days ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

3 weeks ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today reported...

3 weeks ago - Business Wire

Investors almost seemed ready to take profits once shares hit their highest level since February.

4 weeks ago - The Motley Fool

VBI Vaccines Inc (NASDAQ: VBIV) has announced positive Phase 1 data from its Phase 1/2 trial evaluating its enveloped virus-like particle (eVLP) COVID-19 vaccine candidate VBI-2902a. VBI-2902a was well-...

4 weeks ago - Benzinga

These penny stocks are showing high bullish sentiment right now; are they on your watchlist? The post 9 Hot Penny Stocks to Watch With AMC Stock on the Rise Again appeared first on Penny Stocks to Buy, ...

Other stocks mentioned: AUUD, BSQR, ENVB, LKCO, MICT, UEC, XELA
4 weeks ago - PennyStocks

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced...

4 weeks ago - Business Wire

DURHAM, N.C. & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Brii Biosciences (“Brii Bio”) and VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), today announced final results from a Phase 1b/2a study on BRII-179...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

1 month ago - Business Wire

VBI Vaccines (VBIV) has moved higher as of late, but there could definitely be trouble on the horizon for this company

1 month ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of dise...

1 month ago - Business Wire

VBI Vaccines (VBIV) is developing VBI-1901 as a potential treatment of recurrent glioblastoma patients.

1 month ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

1 month ago - Business Wire

The FDA has granted Fast Track Designation for VBI Vaccines Inc's (NASDAQ: VBIV) VBI-1901, its cancer vaccine immunotherapeutic candidate to treat recurrent glioblastoma (GBM) patients with first tumor ...

1 month ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

1 month ago - Business Wire

VBI Vaccines Inc (NASDAQ: VBIV) has announced an agreement to draw down a $12 million second tranche under its previously announced debt financing facility with K2 HealthVentures (K2HV). Under the terms...

2 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

2 months ago - Business Wire

VBI Vaccines Inc (NASDAQ: VBIV) has announced that results from Phase 3 PROTECT trial of VBI's prophylactic 3-antigen hepatitis B (HBV) vaccine candidate in adults were published in The Lancet Infectiou...

2 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

2 months ago - Business Wire

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0.00% and -40.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today reported...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

2 months ago - Business Wire

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

3 months ago - Business Wire

Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient in a Phase 2 trial evaluating BRII-835 (VIR-2218) in combination wi...

Other stocks mentioned: VIR
3 months ago - Benzinga

DURHAM, N.C. & BEIJING & SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Brii Biosciences (Brii Bio), Vir Biotechnology, Inc. (Nasdaq: VIR), and VBI Vaccines Inc. (Nasdaq: VBIV) today announced that ...

Other stocks mentioned: VIR
3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

4 months ago - Business Wire

Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.

Other stocks mentioned: AIM, ASXC, CLSN, IBIO, JAGX, OVID, RIGL
4 months ago - InvestorPlace

The Coalition for Epidemic Preparedness Innovations (CEPI) and VBI Vaccines Inc (NASDAQ: VBIV) entered into a partnership for the development of VBI's enveloped virus-like particle (eVLP) vaccine candid...

4 months ago - Benzinga

VBI Vaccines (VBIV) is developing a monovalent and trivalent COVID-19 vaccines in separate phase I/II studies.

4 months ago - Zacks Investment Research

OSLO, Norway & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--CEPI, the Coalition for Epidemic Preparedness Innovations, and VBI Vaccines Inc. (Nasdaq: VBIV), today announced a partnership to develop VBI'...

4 months ago - Business Wire

VBI Vaccines Inc (NASDAQ: VBIV) initiates enrollment in Phase 1/2 study of VBI-2902, its monovalent enveloped virus-like particle (eVLP), COVID-19 vaccine candidate. The adaptive 60-subject study will e...

4 months ago - Benzinga

OTTAWA, Ontario--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today...

4 months ago - Business Wire

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0.00% and -62.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, toda...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, toda...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

5 months ago - Business Wire

The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causing what's k...

Other stocks mentioned: CLVS, DVAX, LCI, NAKD, OPK, PGEN, SENS ...
5 months ago - Benzinga

VBI Vaccines (VBIV) plans to begin a phase I/II study of monovalent vaccine candidate, VBI-2902, in the first quarter of 2021.

6 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

6 months ago - Business Wire

Esperion Therapeutics (NASDAQ: ESPR) shares are trading lower after Bank of America Securities downgraded the stock from Buy to Neutral and announced a price target of $35 per share. Esprit Holdings is ...

Other stocks mentioned: ESPR, NVS
6 months ago - Benzinga

The company reported good news from a study of its hepatitis B vaccine.

6 months ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

6 months ago - Business Wire

With risk-return not in your favor, steer clear of these 8 penny stocks, all of which could see big declines as the new year unfolds. Chesapeake Energy (OTCMKTS:CHKAQ) Genius Brands (NASDAQ:GNUS) Hertz ...

Other stocks mentioned: CHKAQ, GNUS, HTZGQ, MARK, OCGN, STON, XSPA
6 months ago - InvestorPlace

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

7 months ago - Business Wire

About VBIV

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP progr... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
VBIV
Full Company Profile

Financial Performance

In 2020, VBI Vaccines's revenue was $1.06 million, a decrease of -52.23% compared to the previous year's $2.22 million. Losses were -$46.23 million, -15.66% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for VBI Vaccines stock is "Strong Buy." The 12-month stock price forecast is 8.00, which is an increase of 160.59% from the latest price.

Price Target
$8.00
(160.59% upside)
Analyst Consensus: Strong Buy